Whilst vaccination remains the best protection against COVID-19, the Australian Government continues to ensure that Australians have early access to safe and effective treatments as they are approved for use by the medical experts. This includes the Therapeutic Goods Administration’s (TGA) provisional approval of the first oral anti-viral treatments for COVID-19 in Australia, Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir + ritonavir). These are prescription-only medicines for people who have a high risk of developing severe COVID-19 disease and must be started as soon as possible after a diagnosis of COVID-19. If you are diagnosed as COVID-19 positive, you should immediately notify your GP and your treating neurologist/MS healthcare team to determine if you meet the criteria for treatment with these medications. Commencing 11 July 2022, the eligibility criteria for these COVID-19 oral antiviral treatments have been expanded. See here for more information: Fact sheet – Paxlovid Fact sheet – Lagevrio Fact sheet – Changes to PBS eligibility for COVID-19 treatments